Join the DDA or

Scotland approves new oral PAH medicine

Improved care for patients and carers

May 18th 2018

Tagged: Clinical guidance news

By Ailsa Colquhoun

A new oral medicine for pulmonary arterial hypertension has been approved for use in the NHS in Scotland. A new treatment for severe plaque psoriasis is also among five new medicines to be approved by the Scottish Medicines Consortium, Scotland’s medicines approval body.

Selexipag (Uptravi), which is indicated for pulmonary arterial hypertension (PAH, abnormally high blood pressure in the arteries of the lungs) is an oral treatment taken twice daily. Compared to frequent nebuliser treatment, this is considered to give patients greater freedom to lead a regular daily routine. It will also reduce the care required to support people with the condition.

The SMC Committee also accepted brodalumab (Kyntheum), which extends the range of disease modifying treatment options for patients with severe plaque psoriasis, who have failed to respond to standard therapies.

The other medicines approved are:

  • Nusinersen (Spinraza) for the treatment of infantile onset 5q spinal muscular atrophy (type 1 SMA). SMA is a very rare, genetic, muscle-wasting disease
  • Avelumab (Bavencio) for Merkel cell carcinoma (MCC), an aggressive, rare form of skin cancer.
  • Regorafenib (Stivarga) for advanced liver cancer

For all the latest news of the 2018 DDA annual conference...

Learn more